PAUL HARTMANN AG has acquired Whitestone Acquisition Corp.
The private shareholders of Whitestone Acquisition Corp. have sold the company to PAUL HARTMANN AG (HARTMANN). Financial details have not been disclosed.
HARTMANN, headquartered in Heidenheim, Germany, is a worldwide leader in wound management, incontinence management and risk prevention products in the operating room. Together with the existing US subsidiary, HARTMANN-Conco, Inc. in Rock Hill, South Carolina, HARTMANN consolidates its position in the nursing home and home care sector, the most important market for incontinence products. With this acquisition, the USA will become the third largest market for HARTMANN after Germany and France. The company also sees great opportunities for the establishment of system solutions for inpatient and outpatient care.
Whitestone Acquisition Corp., based in Bloomington, Indiana, is a manufacturer of high-quality adult disposable incontinence products such as briefs, liners and underpads. Formed in 1995, Whitestone annually produces and distributes products for over US$40 million. The corporation primarily serves the institutional long-term care and healthcare markets, markets which are growing 7% a year due to demographic trends.
Oaklins' team in Germany advised HARTMANN on the acquisition of Whitestone Acquisition Corp.
Talk to the deal team
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more